PF-07275315-dose 2

Preclinical

Pfizer

PF-07275315-dose 2 is one of 13 therapeutic programs targeting COPD. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

COPDRecruiting

COPDPreclinical

Recruiting

Competition

Competitive Landscape

17 competitors in COPD

#DrugCompanyPhaseTrials

Spiriva

Boehringer Ingelheim

Approved

13 2

Daliresp

AstraZeneca

Approved

2 3

Striverdi Respimat

Boehringer Ingelheim

Approved

5 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Marinol

Jazz Pharmaceuticals

Phase 3

1 6

Medrol

Pfizer

Preclinical

1 7

Dexpramipexole Dihydrochloride

AAreteia Therapeutics

Phase 2

1 8

DUPIXENT

Regeneron

Preclinical

—9

Xopenex Hfa

HHikma Pharmaceuticals LLC

Preclinical

1 10

Symbicort

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

PreclinicalRecruiting

COPD

NCT07363694

Clinical

Trials by Indication[1]

COPD1 trial

AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07363694·1,156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PF-07275315-dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for PF-07275315-dose 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Pfizer

PF-07275315-dose 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

COPD1 trial

References

Drug Info

Quick Facts

Related News